Gilead Sciences Inc. [NASDAQ: GILD] traded at a high on 12/11/20, posting a 0.51 gain after which it closed the day’ session at $60.76. The company report on December 11, 2020 that Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer.
— sBLA Currently Under Review by the U.S. FDA for Full Marketing Approval in mTNBC –.
Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in this patient population with traditionally poor outcomes.
The results of the trading session contributed to over 7794248 shares changing hands. Over the past one week, the price volatility of Gilead Sciences Inc. stands at 1.47% while the volatility over the past one month is 1.63%.
The market cap for GILD stock reached $75.78 billion, with 1.26 billion shares outstanding and 1.25 billion shares in the current float. Compared to the average trading volume of 9.30M shares, GILD reached a trading volume of 7794248 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Gilead Sciences Inc. [GILD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $73.72 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on November 03, 2020. While these analysts kept the previous recommendation, UBS raised their target price to Neutral. The new note on the price target was released on October 28, 2020, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $78, while Jefferies analysts kept a Buy rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.10, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.27. The Price to Book ratio for the last quarter was 4.37, with the Price to Cash per share for the same quarter was set at 19.22. Price to Free Cash Flow for GILD in the course of the last twelve months was 15.89 with Quick ratio for the last quarter at 3.10.
How has GILD stock performed recently?
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.30. With this latest performance, GILD shares gained by 1.10% in over the last four-week period, additionally sinking by -17.86% over the last 6 months – not to mention a drop of -10.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 47.63, with the RSI for the last a single of trading hit 51.17, and the three-weeks RSI is set at 48.55 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 60.87, while it was recorded at 60.81 for the last single week of trading, and 70.01 for the last 200 days.
Gilead Sciences Inc. [GILD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +22.22 and a Gross Margin at +79.06. Gilead Sciences Inc.’s Net Margin is presently recorded at +24.13.
Return on Total Capital for GILD is now 10.25, given the latest momentum, and Return on Invested Capital for the company is 11.81. Return on Equity for this stock inclined to 24.53, with Return on Assets sitting at 8.60. When it comes to the capital structure of this company, Gilead Sciences Inc. [GILD] has a Total Debt to Total Equity ratio set at 112.40. Additionally, GILD Total Debt to Total Capital is recorded at 52.92, with Total Debt to Total Assets ending up at 41.08. Long-Term Debt to Equity for the company is recorded at 100.87, with the Long-Term Debt to Total Capital now at 47.49.
Reflecting on the efficiency of the workforce at the company, Gilead Sciences Inc. [GILD] managed to generate an average of $456,441 per employee. Receivables Turnover for the company is 6.46 with a Total Asset Turnover recorded at a value of 0.36.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.30.
Earnings analysis for Gilead Sciences Inc. [GILD]
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.3/share EPS, while the average EPS was predicted by analysts to be reported at 1.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 0.06%.
Insider trade positions for Gilead Sciences Inc. [GILD]
There are presently around $59,349 million, or 80.20% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 117,783,804, which is approximately 1.683% of the company’s market cap and around 0.40% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 117,113,247 shares of the stock with an approximate value of $7.12 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.24 billion in GILD stock with ownership of nearly -1.995% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 717 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 45,773,600 shares. Additionally, 831 investors decreased positions by around 62,213,326 shares, while 180 investors held positions by with 868,784,042 shares. The mentioned changes placed institutional holdings at 976,770,968 shares, according to the latest SEC report filing. GILD stock had 109 new institutional investments in for a total of 6,849,704 shares, while 182 institutional investors sold positions of 6,150,429 shares during the same period.